Xeris Biopharma Holdings, Inc. XERS Intangible Amortization
Intangible Amortization at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s intangible amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s intangible amortization?
- Xeris Biopharma Holdings, Inc. (XERS) reported intangible amortization of $2.71M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s intangible amortization changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s intangible amortization decreased by 0.0% year-over-year, from $2.71M to $2.71M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s intangible amortization?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s intangible amortization has grown at a 110.7% compound annual growth rate (CAGR), from $550K to $10.84M.
- What does intangible amortization mean?
- Non-cash amortization of intangible assets (patents, customer relationships, technology) acquired through M&A or purchases.